A promising compound is APR-246 (eprenetapopt), a reconfirming agent of mutated TP53, which has shown unanticipated responses in TP53 mutated AML and MDS patients [151,152,153,154]. This evidence concerns the gene TP53 and acute myeloid leukemia.